Resources from the same session
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in Japanese patients with advanced solid tumors
Presenter: Toshio Shimizu
Session: Developmental therapeutics
Resources:
Abstract
Phase 1 study of safety and tolerability of selinexor in Asian patients with advanced solid cancers: updated results
Presenter: Valerie Heong
Session: Developmental therapeutics
Invited discussant abstracts 127O and 128O
Presenter: Christian Dittrich
Session: Developmental therapeutics
Geographic variations in PK and drug toxicity
Presenter: Alex A. Adjei
Session: Developmental therapeutics
First-in-human study of oral S 49076, a MET/AXL/FGFR inhibitor, in advanced solid tumors
Presenter: Sophie Postel-Vinay
Session: Developmental therapeutics
ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models
Presenter: Byoung Chul Cho
Session: Developmental therapeutics
Resources:
Abstract
A phase I study evaluating the safety, efficacy, pharmacokinetics and pharmacodynamics of AL3810 in advanced solid tumors
Presenter: Athanasios Pallis
Session: Developmental therapeutics
Resources:
Abstract